Now is a great time for employers to consider the impact GI health has on workplace equity and take steps to ensure they’re doing what they can to create an equitable workplace
Oshi Health's $60 million Series C funding round was led by Oak HC/FT and included participation from existing investors Bessemer Venture Partners, Flare Capital Partners, Frist Cressey Ventures, CVS Health Ventures and Takeda Digital Ventures.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Expanded FDA approval of Phathom Pharmaceuticals drug Voquezna now includes patients with non-erosive gastroesophageal reflux disease (GERD). Phathom licensed its flagship product from Takeda Pharmaceutical.
GI disorders are complex, disruptive, and immensely stressful, with physiological, psychological, and sociological implications.
Ironwood Pharmaceuticals is paying $1 billion to acquire VectivBio, a biotech whose lead program could become a blockbuster treatment for a gastrointestinal disorder. Preliminary Phase 3 data are expected by the end of 2023.
Oshi Health raised $23 million in funding, with CVS Health and Takeda joining as strategic investors. The company has built a digital health platform to help people manage GI conditions, such as Crohn’s disease and IBS.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Docbot CEO Andrew Ritter talked about how the predictive analytics business seeks to shake up how clinicians diagnose gastrointestinal disease by changing the way medical images are analyzed.
As awareness grows around GI conditions, startup Oshi Health is building a platform to connect people to teams of clinicians and health coaches to better manage their symptoms. Judges picked the startup as the health services winner for MedCity INVEST’s Pitch Perfect contest.
The companies will evaluate prescription digital therapeutics for patients with gastrointestinal diseases. Pear said it would allow the company to expand beyond its focus on neurological conditions.